JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.
JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.